Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Веза се чува у привремену меморију
СтатусЗавршено
Спонзори
US Oncology Research
Сарадници
Eli Lilly and Company
Sanofi

Кључне речи

Апстрактан

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

Опис

This is a Phase II, open- label, randomized, noncomparative study. Patients will be stratified at randomization by ECOG PS. There is no intent to have equal numbers of patients for each PS (ie, 0, 1, and 2), but rather stratification will be conducted to ensure that the 2 treatment arms are well-balanced for ECOG PS.

Patients will be randomly assigned to either Arm 1 - Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours or Arm 2 - Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes. Taxotere and Eloxatin will be given on Day 1 of each 21-day cycle; ERBITUX is given on Days 1, 8, and 15 of each cycle.

Treatment will continue until disease progression or intolerable toxicity. Patients who achieve a CR will receive an additional 2 cycles of treatment. Patients will be limited to 24 months of participation, counted from the date of the first dose of study drug.

Датуми

Последња верификација: 09/30/2016
Фирст Субмиттед: 08/14/2007
Предвиђена пријава послата: 08/15/2007
Прво објављено: 08/16/2007
Послато последње ажурирање: 10/13/2016
Последње ажурирање објављено: 11/27/2016
Датум првог достављања резултата: 01/11/2016
Датум првог подношења резултата КЦ: 01/11/2016
Датум првог објављивања резултата: 02/10/2016
Стварни датум почетка студије: 06/30/2007
Процењени датум примарног завршетка: 03/31/2012
Предвиђени датум завршетка студије: 03/31/2012

Стање или болест

Gastric Cancer Adenocarcinoma Metastatic

Интервенција / лечење

Drug: Docetaxel

Drug: 2- Docetaxel plus oxaliplatin plus cetuximab

Drug: oxaliplatin

Фаза

Фаза 2

Групе руку

АрмИнтервенција / лечење
Active Comparator: 1- Docetaxel plus Oxaliplatin
Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
Active Comparator: 2- Docetaxel plus oxaliplatin plus cetuximab
Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Drug: 2- Docetaxel plus oxaliplatin plus cetuximab
ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

Критеријуми

Узраст подобан за студирање 18 Years До 18 Years
Полови подобни за студирањеAll
Прихвата здраве волонтереда
Критеријуми

Inclusion Criteria:

- Patient has histologically confirmed Stage IV adenocarcinoma of the GEJ/stomach

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

- Patients must have measurable disease

- Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2

- Patient is greater than 18 years of age

- If present, any pre-existing (current) peripheral neuropathy must be ≤ Grade 1

- Patient's laboratory values must fall within the limits set forth in section 4.2 of the protocol

- Patient has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential)

- If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a 2 month period thereafter

- Patient (or guardian) has signed a Patient Informed Consent Form

- Patient (or guardian) has signed a Patient Authorization Form

Exclusion Criteria:

- Patient has any metastatic disease other than that defined in section 4.2 (criterion #1)

- Patient has had prior treatment that included anything other than adjuvant radiation plus treatment with 5-FU and leucovorin. Prior treatment must have been completed > 6 months prior to registration in current study. No other prior regimens are allowed.

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

- If present, any peripheral neuropathy is > Grade 1

- Patient has a known hypersensitivity to Taxotere (or any drug formulated with Polysorbate-80), or Eloxatin

- Has had a prior severe infusion reaction (Grade 4) to a monoclonal antibody

- Has received prior therapy, at any time, which specifically and directly targets the EGFR pathway

- Patient is receiving concurrent immunotherapy or any other concurrent treatment for their cancer

- Has had prior stem cell or bone marrow transplant or any organ transplant with the exception of corneal transplant or cadaver bone graft

- Has a significant history of uncontrolled cardiac disease; ie, uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, or cardiomyopathy with decreased ejection fraction (LVEF<50%)

- Has evidence of CNS involvement (CNS imaging is not required for study enrollment unless clinically suspected CNS disease is present.)

- Patient has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection

- Patient is known to be HIV positive or have a history of hepatitis B or C

- Patient has a history of other malignancy within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix , or superficial transitional cell carcinoma of the bladder), which could affect the diagnosis or assessment of current condition.

- Patient is a pregnant or lactating woman

Исход

Примарне мере исхода

1. Progression-free Survival [Treatment will continue until disease progression or intolerable toxicity, up to 2 years]

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Секундарне мере исхода

1. Overall Survival [Treatment will continue until disease progression or intolerable toxicity]

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

2. Objective Response Rate (ORR) [Treatment will continue until disease progression or intolerable toxicity.]

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

3. Time to Response [Treatment will continue until disease progression or intolerable toxicity]

For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

4. Duration of Response [Treatment will continue until disease progression or intolerable toxicity]

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

Придружите се нашој
facebook страници

Најкомплетнија база лековитог биља подржана науком

  • Ради на 55 језика
  • Биљни лекови потпомогнути науком
  • Препознавање биљака по слици
  • Интерактивна ГПС мапа - означите биље на локацији (ускоро)
  • Читајте научне публикације повезане са вашом претрагом
  • Претражите лековито биље по њиховим ефектима
  • Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима

Google Play badgeApp Store badge